SCHEMBL10244533

SCHEMBL10244533

COC(=O)NCCN1CCc2ccccc2C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 1/20 0.65
HSD17B10 Q99714 1/20 0.65
SIGMAR1 Q99720 3/20 0.60
ALOX15 P16050 2/20 0.60
MEN1 O00255 1/20 0.60
TP53 P04637 1/20 0.60
KMT2A Q03164 1/20 0.60
MAPT P10636 2/20 0.59
KDM4E B2RXH2 2/20 0.59
CYP1A2 P05177 1/20 0.59
CYP2D6 P10635 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
DRD4 P21917 1/20 0.58
HDAC3 O15379 1/20 0.57
HDAC1 Q13547 1/20 0.57
HDAC8 Q9BY41 1/20 0.57
NCOR2 Q9Y618 1/20 0.57
OPRM1 P35372 1/20 0.56
BCHE P06276 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30945664 1.00 POLB (0.65) POLBHSD17B10SIGMAR1ALOX15MEN1
SCHEMBL30945656 1.00 POLB (0.65) POLBHSD17B10SIGMAR1ALOX15MEN1
SCHEMBL30945677 0.87 DRD2 (0.65) POLBHSD17B10SIGMAR1ALOX15MEN1
SCHEMBL13135946 0.86 ALOX15 (0.62) POLBHSD17B10SIGMAR1ALOX15MEN1
SCHEMBL27246707 0.84 HDAC3 (0.61) POLBHSD17B10ALOX15MEN1TP53
SCHEMBL14720609 0.81 DRD2 (0.72) SIGMAR1ALOX15MEN1TP53KMT2A
SCHEMBL5546764 0.80 HDAC3 (0.68) POLBHSD17B10ALOX15MEN1KMT2A
SCHEMBL15830562 0.80 DRD2 (0.63) SIGMAR1MAPTCYP1A2CYP2D6CYP2C9
SCHEMBL15835822 0.78 PRMT5 (0.65) MAPTCYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL14720434 0.78 SIGMAR1 (0.75) POLBHSD17B10SIGMAR1DRD4ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-8097708-B2 10a-Azalide compound TAISHO PHARMACEUTICAL CO., LTD. (JP) 2012-01-17 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed
US-20090281292-A1 10a-Azalide Compound MEIJI SEIKA PHARMA CO., LTD. (JP) 2009-11-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090281292-A1 10a-Azalide Compound IL17A, AZI2, HDAC9 POLB 3348/4885HSD17B10 178/4885SIGMAR1 3998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.